M3 Biotechnology

Athira Pharma, formerly known as M3 Biotechnology, is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to restore neuronal health and stop neurodegeneration. The company's proprietary platform targets the Hepatocyte Growth Factor (HGF) and its receptor, MET, to promote brain health and function. Their lead candidate, fosgonimeton (ATH-1017), is a small molecule designed to enhance HGF/MET signaling, currently being evaluated for the treatment of Alzheimer's disease and other neurological disorders. Athira's approach aims to provide disease-modifying effects by repairing and protecting neurons rather than just clearing toxic proteins. Headquartered in Bothell, Washington, the company is advancing a pipeline of small molecules for various neurodegenerative and neuropsychiatric conditions.